Pelthos Therapeutics (NYSEAMERICAN:PTHS) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) from a hold rating to a strong sell rating in a research note released on Wednesday,Zacks reports.

Separately, Oppenheimer cut their price objective on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.40.

Pelthos Therapeutics Stock Performance

PTHS opened at $20.50 on Wednesday. The firm’s fifty day simple moving average is $24.40 and its two-hundred day simple moving average is $25.18. Pelthos Therapeutics has a 52-week low of $18.19 and a 52-week high of $37.50. The company has a market cap of $78.52 million, a price-to-earnings ratio of -0.94 and a beta of 3.07. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.The company had revenue of $15.60 million for the quarter. Equities analysts anticipate that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE lifted its stake in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the period. Pale Fire Capital SE owned 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent SEC filing. 77.96% of the stock is owned by institutional investors.

Pelthos Therapeutics Company Profile

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.